Valuation : ARS Pharmaceuticals, Inc.

Market Cap 600M 515M 483M 441M 833M 57.2B 837M 5.72B 2.22B 28.85B 2.25B 2.2B 95.57B P/E 2026 *
-3.3x
P/E 2027 * -7.18x
Enterprise Value 600M 515M 483M 441M 833M 57.2B 837M 5.72B 2.22B 28.85B 2.25B 2.2B 95.57B EV / Sales 2026 *
4.53x
EV / Sales 2027 * 3.06x
Free-Float
83.82%
Yield 2026 *
-
Yield 2027 * -
1 day+5.42%
1 week-5.49%
Current month+17.54%
1 month+1.52%
3 months-26.19%
6 months-35.44%
Current year-48.24%
1 week 5.2
Extreme 5.2
6.09
1 month 4.91
Extreme 4.9102
6.58
Current year 4.91
Extreme 4.9102
13.15
1 year 4.91
Extreme 4.9102
13.46
3 years 2.55
Extreme 2.55
18.9
5 years 2.55
Extreme 2.55
18.9
10 years 2.55
Extreme 2.55
18.9
Manager TitleAgeSince
Chief Executive Officer 53 07/07/2026
Chief Tech/Sci/R&D Officer - 05/08/2015
Director of Finance/CFO 57 01/02/2022
Director TitleAgeSince
Chairman 56 08/11/2022
Director/Board Member 55 01/08/2021
Director/Board Member 56 01/07/2017
Date Insider Type Main position Quantity % Market Cap.
1/7/26 Free

Chief Executive Officer

898,456 0.9048%
24/6/26 Free

Director

30,000 0.0302%
2/1/26 Free

General Counsel

240,000 0.2428%
Change 5-day change 1-year change 3-year change Capi.($)
+5.42%-5.49%-56.59%-13.11% 600M
-0.37%-0.17%+2.17%+22.99% 50.96B
+1.92%+0.36%+477.97%+550.09% 46.18B
-0.15%-0.28%+21.65%+89.41% 42.73B
+0.81%+4.91%+39.28%+19.41% 43.04B
-2.27%-3.02%+14.22%+51.50% 33.48B
+0.81%+1.77%+31.91%+138.26% 17.28B
-1.08%-3.61% - - 16.43B
-0.55%-0.55%+11.14%+27.86% 14.73B
-0.85%+1.76%+80.26%+47.26% 14.09B
Average +0.13%+0.65%+69.11%+103.74% 27.95B
Weighted average by Cap. -0.39%+1.14%+102.96%+138.40%

Financials

2026 *2027 *
Net sales 132M 114M 107M 97.33M 184M 12.62B 185M 1.26B 489M 6.37B 497M 486M 21.08B 196M 168M 158M 144M 272M 18.67B 273M 1.87B 723M 9.42B 735M 719M 31.19B
Net income -182M -156M -147M -134M -253M -17.35B -254M -1.73B -672M -8.75B -683M -668M -28.99B -84.64M -72.65M -68.19M -62.28M -118M -8.07B -118M -807M -313M -4.07B -318M -311M -13.49B
Net Debt - -
Logo ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing neffy, an epinephrine nasal spray indicated in the United States for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult patients and pediatric patients who weigh 33 lbs. or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. neffy is an FDA and European Commission (EC)-approved needle-free epinephrine product, and also has approvals in the United Kingdom, Japan, Australia, and China. It is advancing its nasal spray development program across multiple Type I hypersensitivity reactions, including acute flares of urticaria.
Employees
198
Date Price Change Volume
26/08/26 USD 6.030 +5.42% 1,163,506
25/08/26 USD 5.720 +6.92% 1,715,834
24/08/26 USD 5.350 -2.82% 1,936,733
21/08/26 USD 5.505 0.00% 1,267,922
20/08/26 USD 5.505 -13.71% 2,114,284
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
6.030USD
Average target price
23.25USD
Spread / Average Target
+285.57%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SPRY Stock